🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Efficacy of Oral Contraceptive, Progesterone, and Inositol on Menstrual Regulation in PCOS

RecruitingNAAges 18 Years - 40 YearsFemaleEge University
NCT07242131 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This cross-sectional study aims to compare the effectiveness of oral contraceptives, oral progesterone (didrogesterone), and inositol in regulating menstrual cycles among women diagnosed with polycystic ovary syndrome (PCOS). PCOS is a common endocrine disorder affecting reproductive-aged women and is associated with menstrual irregularities, hyperandrogenism, and polycystic ovarian morphology. While oral contraceptives are the mainstay of treatment, their use may be contraindicated in patients with cardiovascular risk factors, liver dysfunction, or in those who desire pregnancy. This study investigates whether oral progesterone and myo-inositol can serve as effective and safer alternatives for menstrual regulation and improvement of ovarian morphology and hyperandrogenic symptoms. A total of 150 women aged 15-40 years with a diagnosis of PCOS will be enrolled and divided into three e

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Female participants aged 18 to 40 years. * Diagnosed with polycystic ovary syndrome (PCOS) according to the ESHRE/ASRM (Rotterdam) criteria (presence of at least two of the following: oligo/anovulation, clinical or biochemical hyperandrogenism, polycystic ovarian morphology). * No significant comorbid systemic disease. * Willingness to participate and ability to provide written informed consent. * Regular follow-up availability for at least 6 months. Exclusion Criteria: * Known hepatic, renal, cardiovascular, or endocrine disorders other than PCOS. * Pregnancy or current use of hormonal therapy within the past 3 months. * History of thromboembolic disease, breast cancer, or other contraindications to hormonal treatment. * Inability to adhere to follow-up visits or treatment regimen. * Severe cognitive or communication impairment that prevents proper consent or data collection. * Known allergy or hypersensitivity to any component of the study drugs. * Participation in another interventional study within the past 3 months.
💊

What it tests

  • Combined Oral Contraceptive (Ethinylestradiol 0.03 mg + Drospirenone 3 mg)
  • Inositol mid-level volume
  • Dydrogesterone Pill
📍

Where

1 site
Izmir Bakircay University
Izmir, Turkey (Türkiye)
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy